---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006911"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:26:40.612982+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CervoMed selects 50mg TID neflamapimod dose for Phase 3 DLB trial after Phase 1 PK study

## Summary
- Phase 1 healthy volunteer study completed evaluating PK of a new stable crystal form of neflamapimod.
- Selected 50mg three times per day (TID) as dosing regimen for planned Phase 3 dementia with Lewy bodies trial.
- PK profile of 40mg stable crystal form largely overlaps with therapeutically active DP Batch B from Phase 2b extension.
- Dose increased to 50mg TID to ensure plasma drug concentrations match those of the active batch.
- New controlled manufacturing process produces only stable crystal form, mitigating prior polymorph conversion issues.

## SEC filing metadata
- accession: 0001437749-26-006911
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926006911/0001437749-26-006911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926006911/crvo20260304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006911
- JSON: https://secwatch.observer/filing/0001437749-26-006911.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.